<DOC>
	<DOCNO>NCT00870584</DOCNO>
	<brief_summary>This study evaluate effect omalizumab marker impairment patient inadequately control persistent allergic asthma Step 4 therapy define 2007 National Heart , Lung , Blood Institute ( NHBLI ) Guidelines</brief_summary>
	<brief_title>Evaluate Effect Omalizumab Markers Asthma Impairment Patients With Persistent Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Total Asthma Control Test ( ACT ) score ≤19 plus least one follow 4 week precede visit 1 , average : Symptoms &gt; 2 days/week Nighttime awakening ≥1 time/week Shortacting beta2agonist ( SABA ) use symptom control &gt; 2 days/week force expiratory volume 1 second ( FEV1 ) ≤ 80 % predict History intubation asthma . An asthma exacerbation require treatment systemic steroid within 4 week screen ( Visit 1 ) . Less 3 month stable maintenance oral corticosteroid therapy asthma Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Asthma ; asthma management ; asthma impairment ; Xolair ; omalizumab</keyword>
</DOC>